EUCTR2011-002787-25-IT进行中（未招募）1 期
The protein tyrosine kinase inhibitor nilotinib as first-line treatment of Ph+, BCR-ABL+ chronic myeloid leukemia (CML) in early chronic phase: a phase IIIb, multicenter study of complete molecular response - GIMEMA CML0811
G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO0 个研究点目标入组 120 人开始时间: 2012年2月27日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Age = 18 - Male or female patients with diagnosis of Ph+ and/or BCR-ABL+ CML - Early chronic phase (within 6 months from diagnosis) - Pretreatment with Hydroxyurea or Anagrelide for a duration of up to 3 months and/or pretreatment with Imatinib for up to 30 days are permitted - Normal serum levels of potassium, magnesium, total calcium corrected for serum albumin or phosphorus, or correctable to within normal limits with supplements prior to the first dose of study medication - Written informed consent prior to any study procedures being performed - AST and ALT = 2.5 x ULN or = 5.0 x ULN if considered due to leukaemia - Alkaline phosphatase = 2.5 x ULN unless considered due to leukaemia - Total direct bilirubin = 1.5 x ULN, except know Mb. Gilbert - Serum creatinine = 1.5 x ULN
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 80
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •- Known impaired cardiac function, including any of the following: - LVEF < 45% - Complete left bundle branch block - Right bundle branch block plus left anterior hemiblock, bifascicular block - Use of a ventricular-paced pacemaker - Congenital long QT syndrome - History of or presence of clinically significant ventricular or atrial tachyarrhythmias - Clinically significant resting bradycardia (<50 beats per minute) - QTc>450 msec on screening ECG. If QTc > 450 msec and electrolytes are not within normal ranges before otinib dosing, electrolytes should be corrected and then the patient rescreened for QTc criterion. - Myocardial infarction within 12 months prior to starting study drugs - Other clinical significant heart disease (e.g. unstable angina, congestive heart failure, uncontrolled hypertension) - Serum lipase and amylase > 1.5 x ULN (upper limit of normal) or history of acute (i.e., within 1 year of starting study medication) or chronic pancreatitis - Other concurrent uncontrolled medical conditions (e.g., uncontrolled diabetes, active or uncontrolled infections, acute or chronic liver and renal disease) that could cause unacceptable safety risks or compromise compliance with the protocol - Impaired gastrointestinal function or disease that may alter the absorption of study drug (e.g., ulcerative disease, uncontrolled nausea, vomiting and diarrhea, malabsorption syndrome, small bowel resection or gastric by-pass surgery) - Concomitant medications with potential QT prolongation - Concomitant medications known to interact with CYP450 isoenzymes (CYP3A4, CYP2C9, and CYP2C8) - Patients who have undergone major surgery = 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy - Patients who are pregnant or breast feeding, or women of reproductive potential not employing an effective method of birth control. (Women of childbearing potential must have a negative serum pregnancy test within 48 hours prior to administration of nilotinib). - Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention. - Patients unwilling or unable to comply with the protocol.
研究者
相似试验
进行中（未招募）
不适用
A multicenter study to evaluate drug response for the treatment of a white blood cell cancer in early chronic phase.EUCTR2007-000597-22-ITG.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
招募中
不适用
Therapeutic Targeting of Lyn Kinase with Nilotinib to Treat Chorea-Acanthocytosis - an observational, non-interventional studyG23.9Degenerative disease of basal ganglia, unspecifiedDRKS00024187Sektion für Translationale Neurodegeneration Albrecht KosselKlinik und Poliklinik für NeurologieUniversitätsmedizin Rostock10
进行中（未招募）
不适用
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL)MedDRA version: 14.1Level: LLTClassification code 10000844Term: Acute lymphoblastic leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10034877Term: Philadelphia chromosome positiveSystem Organ Class: 10022891 - InvestigationsEUCTR2010-022946-25-Outside-EU/EEAChildren's Oncology Group195
未知
不适用
Tyrosine Kinase Inhibitor for the Treatment of Severe Pulmonary Arterial Hypertensiopulmonary arterial hypertensionJPRN-UMIN000001578Medical Education Center10
已完成
不适用
Discontinuation of tyrosine kinase inhibitor treatment in patients who have obtained complete molecular response after treatment with tyrosine kinase inhibitors for chronic myeloid leukemiaChronic myeloid leukemiaJPRN-UMIN000004798Keio University School of Medicine, Division of Hematology70